|

Evaluation of the Pathobiology of CALR-mutated MPN Cells

RECRUITINGSponsored by Wake Forest University Health Sciences
Actively Recruiting
SponsorWake Forest University Health Sciences
Started2025-01-21
Est. completion2026-07
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations2 sites
View on ClinicalTrials.gov →

NCT06480591

Summary

The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Written (or electronic) informed consent and HIPAA authorization for release of personal health information by participant or his/her legally authorized representative (LAR).
* Age ≥ 18 years at the time of enrollment
* Diagnosis of myeloproliferative neoplasm (MPN) according to 2022 World Health Organization classification of MDS/MPNs
* CALR-positive genetic mutation

Exclusion Criteria:

\- Diagnosis of MPN with JAK2 V617F mutation

Conditions2

CancerMyeloproliferative Neoplasm

Locations2 sites

Atrium Health Levine Cancer
Charlotte, North Carolina, 28204
Courtney Schepel(980) 292-0817Courtney.Schepel@atriumhealth.org
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157
Ruben Mesa, MD336-716-4618ruben.mesa@atriumhealth.org

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.